“…Rapalogs such as everolimus and temsirolimus have been approved for treating breast cancer, neuroendocrine tumors, and renal cell carcinoma [ 27 ]. Several phase I/II trials have also investigated the utility of rapamycin and raplogs in the treatment of mCRC [ 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 ]. Currently, no mTOR inhibitors are available for CRC treatment; however, several dual mTORC1/2 kinase inhibitors in pre-clinical studies have shown potential [ 125 , 126 , 127 , 128 ] and could effectively alleviate the feedback activation of Akt in CRC treatment.…”